Reference
Galizzi N, et al. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLOS One 13: e0191300, No. 2, Part A, 16 Feb 2018. Available from: URL: https://doi.org/10.1371/journal.pone.0191300.t002 - Italy
Rights and permissions
About this article
Cite this article
Abacavir/lamivudine//rilpivirine. Reactions Weekly 1695, 13 (2018). https://doi.org/10.1007/s40278-018-43841-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43841-0